
NAF Statement on FDA Issuing Complete Response Letter for VYGLXIA (troriluzole)
Biohaven announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) seeking approval of VYGLXIA (troriluzole) for the treatment of spinocerebellar ataxia (SCA). A CRL means the FDA has completed its review and determined that the Read More…








